Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

The meeting and exposition will be held from December 7th through the 10th. Deutsche Bank analyst James Shin has lowered his ...

Tesla remains a significant holding for The Future Fund despite position reductions, according to Managing Partner Gary Black ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Size means little in light of this company's prospects.

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

Deutsche Bank lowered the firm’s price target on Eli Lilly (LLY) to $1,015 from $1,025 and keeps a Buy rating on the shares following the ...